Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘NYSE:GKOS’

Dmitry Balyasny of Balyasny Asset Managemnet

Glaukos Corporation (GKOS): Hedge Funds Aren’t Excited

World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients’ money after undertaking a rigorous examination......(read more)
James Flynn Deerfield Management

This Is What Hedge Funds Think About Glaukos Corporation (GKOS)

Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook......(read more)
James Flynn Deerfield Management

Did Hedge Funds Drop The Ball On Glaukos Corporation (GKOS)?

World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients’ money after undertaking a rigorous examination......(read more)
James Flynn Deerfield Management

Hedge Funds Are Betting On Glaukos Corporation (GKOS)

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which......(read more)
doctor, patient, talking, man, male, physician, senior, older, consultant, medical, smiling, people, helpful, adult, desk, working, usa, american, practitioner, horizontal, taking

Hedge Fund Ownership of Glaukos Corp (GKOS) Triples in 3 Quarters: Are You Missing Out?

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the......(read more)
Drew Cupps - Cupps Capital Management

Cupps Capital Slashes Portfolio in Q3, But Couldn’t Stop Buying These 5 Stocks

Drew Cupps‘ Chicago-based asset management firm, Cupps Capital Management, has been in the news of late after it announced that its five-member......(read more)
dating, internet, laptop, date, fun, love, net, sex, key, day, cyberspace, symbol, match, e-mail, technology, computer, partner, relationship, meet, cupid, surfing, pc, find,

Here’s Why Eleven Bio, SouFun, Glaukos, Match Group, and Triumph Group Are Surging Today

U.S. stocks continue to tumble on Wednesday, driven by weak economic data out of the U.S, disappointing corporate financial results, and declining metal......(read more)
SunEdison SUNE Solar Panels

What You Need to Know About These 4 Stocks Deep in the Red Today

Volatility isn’t going away on the 13th day of the year, as all three indexes are now in the red after opening up substantially higher in the morning......(read more)
10 Pharmacist Shortage Countries in Need of Pharmacists in 2017

Do Hedge Funds Love Glaukos Corp (GKOS)?

The worries about the economic slowdown in China and the ongoing uncertainty about the path of interest-rate increases triggered several waves of equity......(read more)
stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart

Why Are These Four Stocks Hot on The Market on Wednesday?

Four stocks jumped into the green territory by midday on November 11 on the back of an Initial Public Offering, the involvement in legal matters, as well......(read more)
Samuel Isaly - Orbimed Advisors

Samuel Isaly’s New Healthcare Positions: Community Health Systems (CYH), Glaukos Corp (GKOS), More

Samuel Isaly’s OrbiMed Advisors is a healthcare fund with $15 billion worth of assets under management. The investment advisory firm has experience......(read more)
Samuel Isaly Orbimed Advisors

Samuel Isaly’s OrbiMed Advisors Discloses Large Stake in Glaukos Corp (GKOS) After Its IPO

Glaukos Corp (NYSE:GKOS) is an $870 million developer of products for the treatment of glaucoma, which conducted its IPO last week with 6.90 million shares......(read more)